Lexicon Pharmaceuticals (LXRX) Return on Sales (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has 17 years of Return on Sales data on file, last reported at 0.0% in Q1 2026.

• On a quarterly basis, Return on Sales rose 22.0% year-over-year to 0.0% in Q1 2026; TTM through Mar 2026 was 0.01%, a 6.0% increase from a year earlier, with the FY2025 full-year figure at 0.01%, up 19.0% from the prior year.
• Return on Sales for Q1 2026 stood at 0.0%, up from 0.03% in the prior quarter.
• Over the last five years, Return on Sales for LXRX reached as high as 0.0% in Q2 2025 and fell as low as 32.68% in Q1 2023.
• Historically, Return on Sales has averaged 6.64% across 5 years, with a median of 0.43% in 2024.
• Across the five-year window, Return on Sales plunged 2499 bps in 2022 and soared 3222 bps in 2024, its largest moves.
• Year by year, Return on Sales stood at 30.05% in 2022, then surged by 98 bps to 0.68% in 2023, then surged by 98 bps to 0.01% in 2024, then slumped by 111 bps to 0.03% in 2025, then jumped by 92 bps to 0.0% in 2026.
• Per Business Quant data, the three most recent Return on Sales figures were 0.0% in Q1 2026, 0.03% in Q4 2025, and 0.01% in Q3 2025.